MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Items 601–700 of 1,006
Liu, R., Wang, W., Wang, S., Xie, W., Li, H., & Ning, B. (2018) · Aging · doi:10.18632/aging.101484 · Cited by 76
“It is worth noting that miR-21 could be a key regulator of fibrosis of several organs [22, 23, 25-28].”
BackgroundMicroRNAs in cardiovascular disease
Gurha, P. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000280 · Cited by 78
Ramos, A. E., Lo, C. T., Estephan, L. E., Tai, Y.-Y., Tang, Y. M., Zhao, J., Sugahara, M., Gorcsan, J., Brown, M. G., Lieberman, D. E., et al. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00741.2017 · Cited by 90
Wu, D., Qin, H., Wang, Z., Yu, M., Liu, Z., Peng, H. F., Liang, L., Zhang, C., & Wei, X. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.829136 · Cited by 80
“, 2011), as well as the regulation of SPRY2 by miR-21 (Thum et al., 2008).”
BackgroundBernardo, B. C., Nguyen, S. S., Winbanks, C. E., Gao, X., Boey, E. J. H., Tham, Y. K., Kiriazis, H., Ooi, J. Y. Y., Porrello, E. R., Igoor, S., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-253856 · Cited by 80
“including apoptosis (14), fibrosis (15, 16), and cardiac”
BackgroundBesler, C., Urban, D., Watzka, S., Lang, D. J., Rommel, K., Kandolf, R., Klingel, K., Thiele, H., Linke, A., Schuler, G. C., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.579 · Cited by 84
MiR-22 may Suppress Fibrogenesis by Targeting TGFβR I in Cardiac Fibroblasts
Hong, Y., Cao, H., Wang, Q., Ye, J., Sui, L., Feng, J., Cai, X., Song, H., Zhang, X., & Chen, X. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453187 · Cited by 84
Burridge, P. W., Sharma, A., & Wu, J. C. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054911 · Cited by 75
“Finally, antisense oligonucleotides called antagomiRs have been utilized to silence the function of miRNAs such as miR-21 to protect mice against cardiac fibrosis (119).”
MethodGrabmaier, U., Clauß, S., Gross, L., Klier, I., Franz, W. M., Steinbeck, G., Wakili, R., Theiss, H. D., & Brenner, C. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.054 · Cited by 80
The Cell Type–Specific Functions of miR-21 in Cardiovascular Diseases
Dai, B., Wang, F., Nie, X., Du, H., Zhao, Y., Yin, Z., Li, H., Fan, J., Zheng, W., Wang, D. W., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.563166 · Cited by 86
He, X., Xie, J., Zhang, D., Su, Q., Sai, X., Bai, R., Chen, C., Luo, X., Gao, G., & Pan, W. (2015) · Hepatology · doi:10.1002/hep.27671 · Cited by 84
“data showed that up-regulation of miR-21 primarily occurred in HSCs during HF, which is different from other fibrotic organs, such as the fibrotic lung in myofibroblasts(6) and the fibrotic kidney in distal tubular epithelial cells.(7,8) Moreover, the regulators of schistosomiasis HF are far more complicated than expe…”
BackgroundMicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases
Li, S., Liang, Z., Liu, X., & Zou, F. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1052-6 · Cited by 82
“Spry1 Cardiac hypertrophy and interstitial fibrosis Cardiac fibroblasts [33]”
InfluentialEngelsvold, D. H., Utheim, T. P., Olstad, O. K., González, P., Eidet, J. R., Lyberg, T., Trøseid, A. S., Dartt, D. A., & Ræder, S. (2013) · Experimental Eye Research · doi:10.1016/j.exer.2013.07.003 · Cited by 82
Nedaeinia, R., Sharifi, M., Avan, A., Kazemi, M., Rafiee, L., Ghayour‐Mobarhan, M., & Salehi, R. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.25 · Cited by 81
Silent Disease Progression in Clinically Stable Heart Failure
Sabbah, H. N. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.705 · Cited by 87
The Impact of Air Pollution on Our Epigenome: How Far Is the Evidence? (A Systematic Review)
Alfano, R., Herceg, Z., Nawrot, T. S., Chadeau‐Hyam, M., Ghantous, A., & Plusquin, M. (2018) · Current Environmental Health Reports · doi:10.1007/s40572-018-0218-8 · Cited by 80
Noncoding RNAs in diabetes vascular complications
Beltrami, C., Angelini, T. G., & Emanueli, C. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.12.014 · Cited by 79
Role of microRNAs in cardiac remodelling: New insights and future perspectives
Orenes‐Piñero, E., Montoro‐García, S., Patel, J. V., Valdés, M., Marín, F. R., & Lip, G. Y. H. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.120 · Cited by 77
The Influence of Diet on MicroRNAs that Impact Cardiovascular Disease
Kura, B., Parikh, M., Slezák, J., & Pierce, G. N. (2019) · Molecules · doi:10.3390/molecules24081509 · Cited by 88
“In the fibrotic mouse, upregulation of miRNA-21 was observed and its inhibition improved the level of fibrosis and heart function [40].”
BackgroundDetection of myocardial fibrosis: Where we stand
Zhu, L., Wang, Y., Zhao, S., & Lu, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.926378 · Cited by 79
“The circulating level of miR-21, one of the most studied miRNAs, has been shown to exert fibrogenic responses (41) and positively correlate with the myocardial expression level of genes encoding type I collagen and fibronectin (42).”
BackgroundDorn, G. W. (2011) · Translational Research · doi:10.1016/j.trsl.2010.12.013 · Cited by 75
MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases
Pan, Z., Lu, Y., & Yang, B. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.175 · Cited by 78
MicroRNAs -the Next Generation Therapeutic Targets in Human Diseases
Sakthivel, S., Selvan, S. T., Archunan, G., Gulyás, B. Z., & Padmanabhan, P. (2013) · Theranostics · doi:10.7150/thno.7026 · Cited by 79
“Some of the major examples that play a high role in this process is two miRNAs, miR-21 and miR-29, which are extensively expressed as miRNAs that are highly augmented in apparently cardiac fibroblasts compared to myocytes [39, 40].”
BackgroundEvaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers
Chen, H., Liu, H., Zou, H., Chen, R., Dou, Y., Sheng, S., Dai, S., Ai, J., Melson, J. E., Kittles, R. A., et al. (2016) · Journal of Cancer · doi:10.7150/jca.12351 · Cited by 80
Alteration of Cardiac Performance and Serum B-Type Natriuretic Peptide Level in Healthy Aging
Yoshida, Y., Nakanishi, K., Daimon, M., Ishiwata, J., Sawada, N., Hirokawa, M., Kaneko, H., Nakao, T., Mizuno, Y., Morita, H., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.080 · Cited by 77
Wang, W., Lin, M., Wang, W., Shen, Z., & Wu, Z. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.025 · Cited by 97
“The aberrant expression or alteration of miRNAs can lead to the occurrence of various diseases, and the detection of intracellular miRNAs is of great significance for early warning of diseases [105,106].”
BackgroundMicroRNAs in Skin and Wound Healing
Banerjee, J., & Sen, C. K. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-083-0_26 · Cited by 86
Regulation of Myocardial Fibrosis by MicroRNAs
Bauersachs, J. K. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181ee81df · Cited by 80
Self-citationThe function of miRNA in cardiac hypertrophy
Wang, J., & Yang, X. Y. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1126-y · Cited by 83
“For example, to test the preventive and curative potential of silencing of miR-21, antagomir-21 was injected into mice subjected to pressure overload of the left ventricle by TAC [41].”
BackgroundMethodMicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention
Karmakar, S., Kaushik, G., Nimmakayala, R. K., Rachagani, S., Ponnusamy, M. P., & Batra, S. K. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.020 · Cited by 78
Involvement of epithelial-mesenchymal transition in liver fibrosis
Li, N., Yu, K., Li, Q., & Shi, G. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_297_17 · Cited by 80
“Thum et al.[75] showed that increased ERK–MAP kinase activity promotes interstitial fibrosis and cardiac function and this process can be inhibited by miR‐21.”
BackgroundEpigenetic associations in relation to cardiovascular prevention and therapeutics
Voelter‐Mahlknecht, S. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0170-0 · Cited by 79
Cardiorenal Syndrome: New Pathways and Novel Biomarkers
Gembillo, G., Visconti, L., Giusti, M. A., Siligato, R., Gallo, A., Santoro, D., & Mattina, A. (2021) · Biomolecules · doi:10.3390/biom11111581 · Cited by 86
“MiR-21 enhances EKR-MAPK activity which leads to fibroblast activation/proliferation causing renal and cardiac fibrosis [80].”
BackgroundNon-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease
Caporali, A., Anwar, M., Devaux, Y., Katare, R., Martelli, F., Srivastava, P. K., Pedrazzini, T., & Emanueli, C. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01001-5 · Cited by 77
“Suppression of miR-21-5p activity provides benefits in the injured heart by limiting myofibroblast proliferation 106 , whereas suppression of miR-21-3p could prevent cardiomyocyte hypertrophic remodelling 107 .”
Post-Transcriptional Regulation of Transforming Growth Factor Beta-1 by MicroRNA-744
Martin, J. T., Jenkins, R. L., Bennagi, R., Krupa, A., Phillips, A. O., Bowen, T., & Fraser, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025044 · Cited by 80
Novel Immune Mechanisms in Hypertension and Cardiovascular Risk
Nosalski, R., McGinnigle, E., Siedliński, M., & Guzik, T. J. (2017) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-017-0537-6 · Cited by 79
Cheng, M., Wu, G., Song, Y., Wang, L., Tu, L., Zhang, L., & Zhang, C. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445554 · Cited by 79
Huang, X., Zhang, Y., Wu, J. P., Chen, J., Wang, S., Wu, J., Ren, L., Zhang, A., Deng, P., Wang, K., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310694 · Cited by 76
Human peripheral blood‑derived exosomes for microRNA delivery
Kang, J., Park, H., Kim, H., Mun, D., Park, H., Yun, N., & Joung, B. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4150 · Cited by 79
“For instance, miR‐21 regulates the extracellular regulated kinase‐mitogen activated pathway kinase signaling pathway in cardiac fibroblasts, which impacts cardiac structure and function (20).”
BackgroundNovel techniques and targets in cardiovascular microRNA research
Dangwal, S., Bang, C., & Thum, T. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr297 · Cited by 78
“endogenous miRNAs (anti-miRs) can be transfected in living cells to modulate expression of the respective miRNA of interest.(19) Sophisticated robotic devices are now available to transfect complete libraries”
BackgroundMethodInfluentialSelf-citationEvidence of epigenetic tags in cardiac fibrosis
Grimaldi, V., Pascale, M. R. D., Zullo, A., Soricelli, A., Infante, T., Mancini, F. P., & Napoli, C. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.004 · Cited by 73
McVicker, B. L., & Bennett, R. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00318 · Cited by 85
“Further, a direct link to profibrotic mechanisms was confirmed when the inhibition of miR-21 via antogomir-21 treatments resulted in recovery of heart function in mice subjected to transverse aortic constriction (Thum et al., 2008).”
BackgroundLong-term inhibition of miR-21 leads to reduction of obesity in db/db mice
Seeger, T., Fischer, A., Muhly-Reinholz, M., Zeiher, A. M., & Dimmeler, S. (2014) · Obesity · doi:10.1002/oby.20852 · Cited by 77
“Both have been shown to be directly targeted by miR21, and Spry1 and Spry2 are negative regulators of the Ras/MEK/ ERK pathway, a pivotal signaling cascade in adipogenic MSC differentiation (11,29,30).”
BackgroundTargeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges
Kwekkeboom, R. F. J., Lei, Z., Doevendans, P. A., Musters, R. J. P., & Sluijter, J. P. G. (2014) · Clinical Science · doi:10.1042/cs20140005 · Cited by 81
Future treatment strategies in ST-segment elevation myocardial infarction
Windecker, S., Bax, J. J., Myat, A., Stone, G. W., & Marber, M. S. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61452-x · Cited by 78
Regulatory RNAs and paracrine networks in the heart
Viereck, J., Bang, C., Foinquinos, A., & Thum, T. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu039 · Cited by 73
“In the last decade, miRNAs have evolved to act as intracellular regulators of gene expression in a variety of cardiovascular disease.(27,28) Since”
BackgroundInfluentialSelf-citationInvolvement of miRNAs in the Differentiation of Human Glioblastoma Multiforme Stem-Like Cells
Aldaz, B., Sagardoy, A., Nogueira, L., Guruceaga, E., Grande, L., Huse, J. T., Aznar, M. A., Díez-Valle, R., Tejada-Solís, S., Alonso, M. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077098 · Cited by 76
“One of the miR-21 predicted targets showing down-regulated expression during GIC differentiation was SPRY1 (Sprouty1) (Figure S4A), a gene that inhibits neural differentiation in mouse embryonic stem cells [29] and has been previously reported as miR-21 target in fibroblasts [30] and keratinocytes miRNAs Involved in G…”
BackgroundNishiga, M., Horie, T., Kuwabara, Y., Nagao, K., Baba, O., Nakao, T., Nishino, T., Hakuno, D., Nakashima, Y., Nishi, H., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.309528 · Cited by 69
Li, X., Li, C., Zhu, G., Yuan, W., & Xiao, Z.-A. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000497829 · Cited by 78
MicroRNA-specific regulatory mechanisms in atherosclerosis
Nazari-Jahantigh, M., Egea, V., Schober, A., & Weber, C. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.10.021 · Cited by 74
“and upregulated in cardiac fibroblasts of the failing heart and activates ERK–MAP kinase signaling, which in turn leads to fibrosis, hypertrophy and cardiac dysfunction [33].”
MicroRNA Profiling of Pericardial Fluid Samples from Patients with Heart Failure
Linna-Kuosmanen, S., Hartikainen, J. E. K., Hippeläinen, M., Kokki, H. J., Levonen, A., & Tavi, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119646 · Cited by 78
“Its expression is deregulated in multitude of cardiovascular disease conditions, including HF [49].”
BackgroundmiR-21 promotes fibrosis in an acute cardiac allograft transplantation model
Gupta, S. K., Itagaki, R., Zheng, X., Bátkai, S., Thum, S., Ahmad, F., Aelst, L. N. L. V., Sharma, A. K., Piccoli, M.-T., Weinberger, F., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw030 · Cited by 72
Self-citationKholia, S., Sanchez, M. B. H., Cedrino, M., Papadimitriou, E., Tapparo, M., Deregibus, M. C., Bruno, S., Antico, F., Brizzi, M. F., Quesenberry, P. J., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00188 · Cited by 70
Biomarkers in Anderson–Fabry Disease
Simonetta, I., Tuttolomondo, A., Daidone, M., & Pinto, A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218080 · Cited by 70
“MicroRNAs (miRNA, miR) are small RNA molecules that have been recently investigated in different disease settings, and they have been reported to have a key role in cardiac function [76,77].”
BackgroundLiu, X., Dong, Y., Chen, S., Zhang, G., Zhang, M., Gong, Y.-Z., & Li, X. (2015) · Cardiology · doi:10.1159/000437090 · Cited by 81
Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts
Turner, N. A., & Porter, K. E. (2012) · IUBMB Life · doi:10.1002/iub.594 · Cited by 73
“MiRs act in a highly tissue- and cell type-specific manner and their roles in CF differ from those in cardiomyocytes (19, 36, 37), supporting the proposition that miRs present novel and realistic therapeutic targets.”
BackgroundArata, H. F., Komatsu, H., Hosokawa, K., & Maeda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048329 · Cited by 79
“MiR-21 was adopted as a model sequence since it is one of the most well-known miRNAs as a cancer marker [36,37].”
MicroRNAs in the tumor endothelium: Novel controls on the angioregulatory switchboard
Heusschen, R., van Gink, M., Griffioen, A. W., & Thijssen, V. L. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.09.005 · Cited by 73
Ward, J. A. (2013) · Family Medicine & Medical Science Research · doi:10.4172/2327-4972.1000108 · Cited by 71
“MiRNA-21 has been associated with interstitial fibrosis and cardiac hypertrophy and miRNA-320 with cardiac ischemia and reperfusion injury, respectively [33,34].”
BackgroundUsui‐Ouchi, A., Ouchi, Y., KIYOKAWA, M., Sakuma, T., Ito, R., & Ebihara, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158043 · Cited by 72
“These miRNAs have previously been reported to play important roles in the regulation of tissue fibrosis, including idiopathic pulmonary fibrosis [20, 24], cardiac fibrosis [18], systemic sclerosis [22], MicroRNAs in the Vitreous of Proliferative Vitreoretinal Disease”
BackgroundMarca, V. L., & Fierabracci, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091974 · Cited by 71
“The same authors focused their studies also on miR-21, a profibrotic miRNA in cardiovascular diseases [109], known to induce fibrosis in many organs including heart and kidney [109,110] and involved in endothelial-to-mesenchymal transition [111].”
BackgroundBageghni, S. A., Hemmings, K. E., Zava, N. K., Denton, C. P., Porter, K. E., Ainscough, J., Drinkhill, M. J., & Turner, N. A. (2018) · The FASEB Journal · doi:10.1096/fj.201701455rr · Cited by 80
Age-dependent increase of oxidative stress regulates microRNA-29 family preserving cardiac health
Heid, J., Cencioni, C., Ripa, R., Baumgart, M., Atlante, S., Milano, G., Scopece, A., Kuenne, C., Guenther, S., Azzimato, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16829-w · Cited by 70
MicroRNAs in pulmonary arterial remodeling
Grant, J. S., White, K., MacLean, M. R., & Baker, A. H. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1382-5 · Cited by 74
“Tissues taken from patients with heart failure and animal models of cardiac disease show an up-regulation of miR-21 [104, 105].”
BackgroundHeart failure: advances through genomics
Creemers, E., Wilde, A., & Pinto, Y. (2011) · Nature reviews genetics · doi:10.1038/nrg2983 · Cited by 70
“Several miRNAs, such as miR-133, miR-208, miR-21 and miR-29, have been experimentally implicated in various aspects of heart failure (for example, hypertrophy, fibrosis, cardiac conduction and angiogenesis”
Smigielska‐Czepiel, K., van den Berg, A., Jellema, P. G., Ślęzak-Prochazka, I., Maat, H., van den Bos, H., van der Lei, R. J., Kluiver, J. L., Brouwer, E., Boots, A. M. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076217 · Cited by 72
“Amongst these, miR-21 has anti-apoptotic properties which have been extensively studied in pathological conditions including cancer, cardiovascular disease and autoimmunity [11-14].”
Li, C., Bai, Y., Liu, H., Zuo, X., Yao, H., Xu, Y., & Cao, M. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt057 · Cited by 70
Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?
Prattichizzo, F., Giuliani, A., Nigris, V. D., Pujadas, G., Çeka, A., Sala, L. L., Genovese, S., Testa, R., Procopio, A. D., Olivieri, F., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12688 · Cited by 73
“Moreover, it plays a crucial role in cardiac fibrosis and related heart failure in a mouse pressure-overload-induced model [79], an effect that seems to be mediated by miR-21* contained in fibroblast-derived exosomes [80].”
BackgroundO’Reilly, S. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.10.001 · Cited by 79
Regulating microRNA expression: at the heart of diabetes mellitus and the mitochondrion
Hathaway, Q. A., Pinti, M. V., Durr, A. J., Waris, S. A., Shepherd, D. L., & Hollander, J. M. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00520.2017 · Cited by 69
“(138) showed that administering an antagomiR specific”
Kim, K. W., Lee, S. J., Park, S. H., & Kim, J. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800398 · Cited by 72
The association between microRNA-21 and hypertension-induced cardiac remodeling
Watanabe, K., Narumi, T., Watanabe, T., Otaki, Y., Takahashi, T., Aono, T., Goto, J., Toshima, T., Sugai, T., Wanezaki, M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226053 · Cited by 72
“(A) The mRNA expressions of Smad7, PTEN, and Spry1 after treatment with vehicle or Ang II for 24 h in NRCMs (n = 4–6 per group).”
BackgroundInfluentialRegulation of cardiac and renal ischemia–reperfusion injury by microRNAs
Lorenzen, J. M., Bátkai, S., & Thum, T. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.044 · Cited by 71
Self-citationLiu, Z., Ye, P., Wang, S., Wu, J., Sun, Y., Zhang, A., Ren, L., Cheng, C., Huang, X., Wang, K., et al. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000598 · Cited by 71
Ramanujam, D. P., Sassi, Y., Laggerbauer, B., & Engelhardt, S. H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.166 · Cited by 73
Self-citationEmerging Evidence of Epigenetic Modifications in Vascular Complication of Diabetes
Khullar, M., Cheema, B. S., & Raut, S. K. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00237 · Cited by 70
“Liu et al. demonstrated increased miR-21 expression after high glucose treatment in cardiac fibroblasts (92). miR-21 was shown to promote fibroblast survival by down regulating SPRY1 (93).”
BackgroundZhou, Q., Maleck, C., von Ungern‐Sternberg, S. N. I., Neupane, B., Heinzmann, D., Marquardt, J., Duckheim, M., Scheckenbach, C., Stimpfle, F., Gawaz, M., et al. (2018) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.118.006242 · Cited by 70
Inhibition of miR‐21 alleviated cardiac perivascular fibrosis via repressing EndMT in T1DM
Li, Q., Yao, Y., Shi, S., Zhou, M., Zhou, Y., Wang, M., Chiu, J., Huang, Z., Zhang, W., Liu, M., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14800 · Cited by 74
MicroRNA and nephropathy: emerging concepts
Lan, H. Y., Chung, A. C. K., & Yu, X. (2013) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s37885 · Cited by 75
“40 Furthermore, both TGF-β 1 and TGF-β 2 suppress miR-200a expression in renal cells.”
InfluentialEpigenetic mechanisms in coronary artery disease: The current state and prospects
Duan, L., Liu, C., Hu, J., Liu, Y., Wang, J., Chen, G., Li, Z., & Chen, H. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.012 · Cited by 68
Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice
Jia, K., Dai, Y., Liu, A., Li, X., Wu, L., Lu, L., Bao, Y., & Jin, Q. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000878 · Cited by 64
Research Advances in Heart Failure: A Compendium
Braunwald, E. (2013) · Circulation Research · doi:10.1161/circresaha.113.302254 · Cited by 87
“MiR-21 has been shown to be regulated and to be increased in fibroblasts, in which it stimulates interstitial fibrosis.(66) When myocardial necrosis occurs, activated interstitial fibroblasts are transformed into myofibroblasts, which enhance fibrogenesis, culminating in a scar, a process that is analogous to wound he…”
BackgroundHeger, J., Schulz, R., & Euler, G. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13344 · Cited by 72
“In the context of heart failure progression, miR21 should be highlighted; miR21 is selectively up-regulated in fibroblasts upon TGFβ stimulation, and in the failing myocardium (Thum et al., 2008; Topkara and Mann, 2011).”
BackgroundPlank, M. W., Maltby, S., Tay, H. L., Stewart, J., Eyers, F., Hansbro, P. M., & Foster, P. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144810 · Cited by 72
Schelbert, E. B., Sabbah, H. N., Butler, J., & Gheorghiade, M. (2017) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.005619 · Cited by 71
Joris, V., Gomez, E. L., Menchi, L., Lobysheva, I. I., Mauro, V. D., Esfahani, H., Condorelli, G., Balligand, J., Catalucci, D., & Dessy, C. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311145 · Cited by 69
Stimulating Cardiogenesis as a Treatment for Heart Failure
Heallen, T. R., Kadow, Z. A., Jong Heon, K. I. M., Wang, J., & Martin, J. F. (2019) · Circulation Research · doi:10.1161/circresaha.118.313573 · Cited by 75
Review focus on the role of microRNA in cardiovascular biology and disease
Thum, T., & Mayr, M. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs085 · Cited by 73
Self-citationMicroRNAs in diabetes and diabetes-associated complications
Lorenzen, J. M., Kumarswamy, R., Dangwal, S., & Thum, T. (2012) · RNA Biology · doi:10.4161/rna.20162 · Cited by 75
“, miR-21 and miR-29 in cardiac fibrosis).(6,7) Thus, a critical disturbance of downstream gene networks and signaling cascades associated with disease initiation might ensue following deregulation of miRNAs.”
BackgroundSelf-citationThe Therapeutic Potential of Mirnas Regulated in Settings of Physiological Cardiac Hypertrophy
Ooi, J. Y., Bernardo, B. C., & McMullen, J. R. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.196 · Cited by 66
Villar, A. V., García, R., Llano, M., Cobo, M., Merino, D., Lantero, A., Tramullas, M., Hurlé, J. M., Hurlé, M. A., & Nistal, J. F. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.007 · Cited by 86
MicroRNAs and vascular (dys)function
Hartmann, D., & Thum, T. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.07.005 · Cited by 75
Self-citationSantiago, J., McNaughton, L. J., Koleini, N., Ma, X., Bestvater, B. P., Nickel, B. E., Fandrich, R. R., Wigle, J. T., Freed, D. H., Arora, R. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097281 · Cited by 74
“The present study shows that the Ang II-induced Hi-FGF-2 upregulation requires the ERK activating pathway, in agreement with previous work regarding expression of FGF-2 of unknown isoform composition by cardiac fibroblasts [7,55].”
BackgroundResultInfluentialDNA Damage and Repair in Atherosclerosis: Current Insights and Future Perspectives
Cervelli, T., Borghini, A., Galli, A., & Andreassi, M. G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131216929 · Cited by 71
“function [84].”
Role of microRNA-21 in regulating 3T3-L1 adipocyte differentiation and adiponectin expression
Kang, M., Yan, L., Zhang, W.-Y., Li, Y., Tang, A., & Ou, H. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2603-6 · Cited by 70
MicroRNAs-mediated epithelial-mesenchymal transition in fibrotic diseases
Zou, X., Liu, T. C., Gong, Z., Hu, C.-P., & Zhang, Z. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.12.003 · Cited by 69
Li, X., Zeng, Z., Li, Q., Xu, Q., Xie, J., Hao, H., Luo, G., Liao, W., Bin, J., Huang, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4774 · Cited by 65
“Accumulating evidence indicates the importance of several miRNAs in affecting myocardial IR injury [7-12], raising the possibility of making them potential therapeutic targets.”
Michalska, M., Bielecka-Dabrowa, A. M., von Haehling, S., Anker, S. D., Rysz, J., & Banach, M. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.76279 · Cited by 77
MicroRNA-21 suppression impedes medulloblastoma cell migration
Grunder, E., D’Ambrosio, R., Fiaschetti, G., Abela, L., Arcaro, A., Zuzak, T. J., Ohgaki, H., Lv, S., Shalaby, T., & Grotzer, M. A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.041 · Cited by 67
“A photometric enzyme immunoassay (Cell Death Detection ELISA; Roche Diagnostics, Basel, Switzerland) was used for the quantitative determination of cytoplasmic histone-associated DNA fragments, as described previously.(49) In brief, an equal number of MB cells were seeded in a six-well plate and were either transfecte…”
Sygitowicz, G., Tomaniak, M., Błaszczyk, O., Kołtowski, Ł., Filipiak, K. J., & Sitkiewicz, D. (2015) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2015.07.003 · Cited by 67
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.